Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver transplant bleeding study pulled before starting

NCT ID NCT06764927

Disease control Sponsor: Ezeldeen Abuelkasem Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to see if a new concentrated fibrinogen product works better than the standard one for controlling bleeding in liver transplant patients. It planned to enroll adults having a cadaveric liver transplant who were at risk for low fibrinogen levels. However, the study was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Scheduled to undergo cadaveric liver transplant * Meets at least one of the following criteria: * Baseline fibrinogen \<200 mg/dL * Alcoholic cirrhosis * Nonalcoholic Steatohepatitis (NASH) * HCV infection Exclusion Criteria: * Living related donor transplant * DCD liver recipient * Known prothrombotic disorder * Patient objection to blood transfusion * Known severe allergic reaction to plasma-based products * IgA deficiency with known hypersensitivity reaction to plasma * Hepatocellular/cholangio carcinoma * Primary biliary fibrosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver disease requiring transplant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver transplant surgery

Contacts and locations

Locations

  • UPMC Montefiore Hospital

    Pittsburgh, Pennsylvania, 15213, United States

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.